Taipei, July 21, 2023 - PharmaEssentia (Stock Code: 6446), a leading company dedicated to the research and development of rare blood diseases, celebrates its global success in launching a long-acting interferon product in over 30 countries. As a significant contributor in the field, PharmaEssentia takes great pride in spearheading the MPN Asia International Conference, an event aimed at promoting sustainable health and social inclusion. The company is committed to achieving universal health coverage and promoting health equity on a global scale. 

PharmaEssentia's unwavering commitment to innovation and its social impact within the field of rare blood diseases, particularly in MPN (Myeloproliferative Neoplasms), has garnered high acclaim. At the highly regarded 2nd APSAA Asia-Pacific Sustainable Action Awards and the 3rd TSAA Taiwan Sustainable Action Awards, organized by the Taiwan Corporate Sustainability Awards committee, PharmaEssentia's MPN Asia Conference was honored as a core sustainable action project, receiving the esteemed APSAA Silver Award and TSAA Bronze Award. These accolades serve as a testament to PharmaEssentia's significant contributions and social influence within the MPN field. 

Since its inception in 2016, the MPN Asia International Conference has successfully convened for the sixth consecutive year, hosting events across four cities in Asia. The conference has served as a gathering of renowned experts, scholars, and opinion leaders, facilitating the exchange of cutting-edge research and breakthroughs in drug development, treatment methodologies, and crucial clinical insights. The event has captured the attention and participation of international hematologists and experts in the field of blood malignancies. PharmaEssentia remains committed to expanding the conference's sustainability and fostering academic exchanges and clinical collaborations within the MPN field across the Asia-Pacific region. Through the establishment of a diverse, open, cooperative, and mutually beneficial MPN community, the company aims to contribute to the creation of a resilient global healthcare system. By focusing on drug development and disease management in the MPN field, PharmaEssentia endeavors to generate greater societal value. This innovative approach to advocacy and communication strategies not only addresses the three facets of ESG sustainability but also fosters shared value for patients, aligning with the vision of sustainable health and well-being encapsulated in SDG3.

PharmaEssentia plays a pivotal role in achieving several Sustainable Development Goals (SDGs), including the eradication of poverty, the promotion of health, the provision of education, the facilitation of economic growth, the reduction of inequalities, and the establishment of robust healthcare systems. The company remains dedicated to improving the quality of life and survival rates of MPN patients, enhancing the efficiency of healthcare resources, and promoting social inclusion on both the international and local levels. PharmaEssentia firmly believes that by fostering a diverse, open, cooperative, and mutually beneficial MPN community, while advancing drug development and disease management, it can create substantial societal value. 

For further information, please visit PharmaEssentia's Sustainable ESG website at http://www.pharmaessentia-esg.com 

or contact the Corporate Sustainability Development Center at CSR-ESG@pharmaessentia.com. 

Media inquiries may be directed to Ms. Shu-Fen Li, Senior Director, at +886-2-26557688 (ext. 7839).